NIHR | Cambridge Biomedical Research Centre

CUH Patient and Public Involvement Summer 2024 Newsletter

News and updates on PPI in the East of England



Welcome to the Summer 2024 edition!

Please mark your calendars for our upcoming events, webinars and gatherings, both virtual and in-person. This quarterly update is your go-to source for the latest news on local and national events, PPI developments, engaging research articles and more!

Please email **cuh.ppi@nhs.net** to update your choices if you would prefer to be removed from our subscriber list.

Research Information talks 2024

These talks are open to anyone involved in research across Cambridge and the links will be shared with both CUH PPI panel members and public involvement and engagement staff in our network.

What research information talks would you like to see next?
Please email **cuh.ppi@nhs.net** with any ideas, suggestions, or requests for information talks.

Some of our earlier talks, soon to be on YouTube:

- **Systematic Reviews: What They Are, Why They Matter, How They Work and Where Do You Fit In?**

  Systematic reviews (SR) are a valuable research output in their own right, and can help to justify and focus primary research. But what are they, why are they so valuable, and how can you contribute? Veronica Phillips and Isla Kuhn will introduce you to SRs and highlight ways in which you, as expert patients, might get involved.
- **What is cell therapy?**

  Cell therapy refers to placing new, healthy cells into the body to replace diseased or damaged ones, to modulate the function of the patient's cells through expression of factors or direct interaction, or the removal of disease-causing or dysfunctional cells using immune cells. Professor Barker combines basic research looking at novel therapies to treat chronic neurodegenerative disorders of the brain with clinically-based work aimed at better defining such disorders.

Our YouTube channel link

www.youtube.com/@nihrcambridgebrc6564

If you are a researcher who would like to contribute to this series, or if you have public contributors who may wish to attend, please get in touch at **cuh.ppi@nhs.net**

Join the CUH PPI panel to help bring about positive changes in research

We are always looking for new members to join the CUH PPI panel and engage in ongoing research at Cambridge University Hospitals and the NIHR Cambridge Biomedical Research Centre.

Joining the CUH PPI panel is free and open to the public, ages 16 and above, who live in the **East of England** and are not currently working in **health research** or the **media**. Panel members can choose from various research projects to get involved in, with opportunities available online, digitally and in person.

Click here to read more

Watch our PPI strategy lead and panel members talk about being involved in research:

https://youtu.be/x3ZaCdXLVJs

Researchers' feedback to CUH PPI panel members

Things have been a bit quieter lately, but your help still made a big difference! How do you think your involvement has impacted their research?

Take a look at the feedback they gave on the various research projects **Click here**
Feedback has been shared from projects conducted in 2024.

These files are password-protected and only available to CUH PPI panel members.

Past Events

The role of a SAB and why it's important

A personal reflection from Professor Miles Parkes, Director of NIHR Cambridge Biomedical Research Centre (BRC)

Every two years, something very special happens in the life of the NIHR Cambridge BRC and it's something we all look forward to hugely.

It's when our international Scientific Advisory Board (or SAB) of leaders in biomedical research joins us over two days as 'critical friends', to hear about our early translational research (research fresh from the laboratory, exploring how it can be applied in people to sustain health and treat disease), review its quality and provide strategic direction. The meeting also provides an opportunity for us and our partners to come together to celebrate our successes and take a critical look at ourselves. This whole process is crucial, not only for our governance but to hold us accountable for the research we do.

In April this year, meeting in the Cancer Research UK Cambridge Institute, I welcomed our SAB and a large audience with a brief introduction to the biomedical campus with its rich inter-digitation of healthcare, research, and industry facilities. The BRC plays a key role in supporting early translational research infrastructure, enabling projects led by our investigators and their partners. Many of these projects involve extensive collaborations and reach beyond the campus to our region and nationally.

After my introduction, I handed over to the leads of our 13 research themes for a sequence of presentations on their ground-breaking research and its impact. Their emphasis is absolutely on priorities identified by patients, and how our research can best address their concerns and health priorities. None of our research would happen without patients – and so we had talks on our patient and public involvement and equality and diversity work, and an opportunity for the SAB and others to see first-hand the new Clinical Research Facility (a place for participants to take part in research) in the Victor Phillip Dahdaleh Heart and Lung Research Institute.

Over two days, we enjoyed lots of opportunities to ask questions and give feedback – including where we can improve. There was lots of thought-provoking discussion about the direction of research and how we can develop new diagnostics and treatments for some of our biggest health challenges.

Having an event like this is critical to our work – highlighting the successes but also providing an opportunity for constructive criticism. I was delighted to see the SAB members so engaged, see so many staff in the audience – and receive so many positive comments regarding the important research we do in Cambridge.

But please don't just take my word for it; watch our short video and hear for yourself why our attendees think that our biomedical campus, supported by the NIHR Cambridge BRC, is a special place to conduct health research.

Video link: https://youtu.be/TVujDDqoFoc

Patient and Public Involvement week returns and is a huge hit!

Nearly 200 people attended an exciting week of Patient and Public Involvement events at the end of June. This was the first event of its kind held on the Cambridge Biomedical Campus.

Hosted by the NIHR Cambridge Biomedical Research Centre (BRC), University of Cambridge and Anglian Ruskin University (ARU), the event aimed to celebrate and raise awareness of Patient and Public Involvement (PPI) in health research.

The week began with a webinar for members of the public who were able to hear how people's voices can help shape health and care research and opportunities to get involved in research through CUH, NIHR Cambridge BRC, Anglia Ruskin University and other health and research partners across the region. The 90-minute webinar highlighted the importance of PPI in health research and attendees heard about some of the examples of activities the NIHR Cambridge BRC PPI panel members are involved in.

On Tuesday we held a public PPI showcase of talks and poster exhibits from health researchers, where they explained how patient and public involvement had made an impact to their research. Attendees were able to network and vote for the best poster and talks from the morning and afternoon sessions. The all-day event received excellent feedback, with one saying: "I just wanted to give a big thank you. It's really important to have an event where you can find out about what is going on in Cambridge and the PPI space."

Wednesday provided an opportunity to learn from our partners at ARU about their 'Let's Shape Research Together' public involvement programme. Their annual conference showcases case studies as well as keynote speakers from PPIE experts across Cambridgeshire.

The final event of the week was a market stall drop-in at the Dunn Suite in CUH, where staff and members of the public could meet health and research patient and public involvement teams from Cambridgeshire, from the NIHR Cambridge BRC, Cambridge Biomedical Campus local voices, CRUK, IMS and Stem Cell, Cambridge School of Biology, Cambridge Clinical School, Cambridge Children's Hospital, ACTIVE and CUH members. The organisations were able to provide more information on how people could volunteer to their panels and offer staff support and advice on their PPI projects. One attendee said, "It was a great event, I had some really valuable conversations with the staff."

Dr Amanda Stranks, PPI and communications strategy lead from NIHR Cambridge BRC and one of the organisers said: “This week of PPI events gave us the chance to celebrate and showcase some of the best examples of patient and public involvement in research that are happening on the Cambridge Biomedical Campus. The variety and quality of the examples are testament to how researchers and our public are working in partnership across Cambridge to produce life-changing research.

“Patient and Public Involvement makes such a difference to the research we do here in Cambridge. We need public voices to make sure we are doing the best research we can, and that our research opportunities are widely accessible and meet patient’s needs. Showcasing examples of how the public makes a difference to our research and our researchers helps encourage more researchers and members of the public to get involved.

“We’re really pleased by the response of staff and the public to the week’s activities and would like to extend our thanks to all who came and supported the events. We received some amazing feedback and are delighted to see an increase in sign-ups for some of the Cambridgeshire panels. We’re looking forward to seeing everyone next year for an even bigger regional public involvement week!

Upcoming Events

NIHR Cambridge BRC Public Open Evening



Theme: Translational advances in Inflammation

Date: 10 October 2024

A free in-person event for members of the public, carers, patients and staff as we highlight local research on inflammation.

Inflammation is an essential part of how we fight off infection. However, sometimes it persists even after an infection clears, happens in the wrong place, or kicks off even without any signs of infection and results in a range of health conditions that reduce quality of life for patients.

Join us for an hour of talks either in the afternoon (4-5 pm) or evening (6-7 pm) on the latest developments in inflammation research at NIHR Cambridge BRC and take the opportunity to chat with local researchers about their research.

There will be a poster-and-networking session with a light lunch and refreshments in between the repeated talks; you only need to book one session to attend the talks and poster exhibition.

If you have any questions, please contact Georgina Norris on gan23@cam.ac.uk

Cambridge Wellness Festival

10 September

The Cambridge Wellness Festival returns for the second year!

11 am until 6 pm

Join us on The Green on the Cambridge Biomedical Campus between Royal Papworth Hospital and AstraZeneca.

You can't miss us; just look out for the tents and the festival flags!

Find us on What3Words here.

We've got an incredibly exciting day planned come rain or shine in our huge stretch tents on the Green. There is no charge for entry and no charge for anything except refreshments and as an added bonus, all our activities run throughout the day, whatever time you arrive! No pre-booking required – just turn up!

Click here to download the programme

Survey

East of England Secure Data Environment Public and Researcher Engagement

Thank you to everyone who has contributed to the survey for the East of England Secure Data Environment so far - we've had more than 120 responses and are hoping to continue to build on that!



So far, respondents have told us that their key concerns about having their NHS data used through the SDE are the security of the data, commercial companies accessing the data and that their data wont be kept private - we're

using this feedback to develop the SDE and to help us understand what information is important to include in our public and researcher materials.

Have you completed the survey yet? Whether you're a health professional, researcher or member of the public - we want to hear from you! Please share your thoughts about using NHS data for research at https://forms.office.com/e/Z78PiacwQ7

We're looking for more places to share the survey and to send information about the SDE - if you're part of a patient or community group that would like to hear more about the SDE and how it will use your data, please get in touch at a.stranks@nhs.net

---

PEDRI 2024 Resources Survey

We are looking for anyone working in data science with a connection to public engagement to take part in our PEDRI resource survey.

PEDRI (Public Engagement in Data Research Initiative) is a new, sector-wide partnership that unites organisations to share knowledge, good practice, and collaborate on public involvement and engagement (PIE) in data research and statistics. One of our primary goals is to address resource and information gaps for professionals and researchers. By taking part in our survey, you can help us identify existing resources you have created or use, discover information gaps and help shape an online resources hub hosted on the new PEDRI website. This hub will be freely accessible to everyone working in data research and statistics.

The survey will be open until **30th August 2024** and should take around 10 minutes to complete: https://forms.office.com/e/FSHWdNVvby

Feel free to contact the team at contact@pedri.org.uk with any questions.

Articles

Cambridge researchers have been elected as Fellows of the Royal Society, the UK's national academy of sciences and the oldest science academy in continuous existence

The Royal Society is a self-governing Fellowship of many of the world's most distinguished scientists, drawn from all areas of science, engineering and medicine.

The Society's fundamental purpose, as it has been since its foundation in 1660, is to recognise, promote and support excellence in science and to encourage the development and use of science for the benefit of humanity.

This year, over 90 researchers, innovators and communicators from around the world have been elected as Fellows of the Royal Society for their

substantial contribution to the advancement of science. Nine of these are from the University of Cambridge.

Sir Adrian Smith, President of the Royal Society, said: “I am pleased to welcome such an outstanding group into the Fellowship of the Royal Society.

“This new cohort have already made significant contributions to our understanding of the world around us and continue to push the boundaries of possibility in academic research and industry.

“From visualising the sharp rise in global temperatures since the industrial revolution to leading the response to the Covid-19 pandemic, their diverse range of expertise is furthering human understanding and helping to address some of our greatest challenges. It is an honour to have them join the Fellowship.”

The Fellows and Foreign Members join the ranks of Stephen Hawking, Isaac Newton, Charles Darwin, Albert Einstein, Lise Meitner, Subrahmanyan Chandrasekhar and Dorothy Hodgkin.

The new Cambridge fellows are:

Professor Sir John Aston Kt FRS

Aston is the Harding Professor of Statistics in Public Life at the Statistical Laboratory, Department of Pure Mathematics and Mathematical Statistics, where he develops techniques for public policy and improves the use of quantitative methods in public policy debates.

From 2017 to 2020, he was the Chief Scientific Adviser to the Home Office, providing statistical and scientific advice to ministers and officials, and was involved in the UK’s response to the Covid pandemic. He was knighted in

2021 for services to statistics and public policymaking, and is a Fellow of Churchill College.

Professor Sarah-Jayne Blakemore FBA FMedSci FRS

Blakemore is the Professor of Psychology and Cognitive Neuroscience, Department of Psychology, and leader of the Developmental Cognitive Neuroscience Group. Her research focuses on the development of social cognition and decision making in the human adolescent brain and adolescent mental health.

Blakemore has been awarded several national and international prizes for her research and is a Fellow of the British Academy, the American Association of Psychological Science and the Academy of Medical Sciences.

Professor Patrick Chinnery FMedSci FRS

Chinnery is Professor of Neurology and head of the University's Department of Clinical Neurosciences, and a Fellow of Gonville & Caius College. He was appointed Executive Chair of the Medical Research Council last year, having previously been MRC Clinical Director since 2019.

His principal research is the role of mitochondria in human disease and developing new treatments for mitochondrial disorders. Chinnery is a Wellcome Principal Research Fellow with a lab based in the MRC Mitochondrial Biology Unit and jointly chairs the NIHR BioResource for Translational Research in Common and Rare Diseases. He is a Fellow of the Academy of Medical Sciences.

Professor Rebecca Fitzgerald OBE FMedSci FRS

Fitzgerald is Professor of Cancer Prevention in the Department of Oncology and the inaugural Director of the University's new Early Cancer Institute, which launched in 2022. She is a Fellow of Trinity College.

Her pioneering work to devise a first-in-class, non-endoscopic capsule sponge test for identifying individuals at high risk for oesophageal cancer has won numerous prizes, including the Westminster Medal, and this test is now being rolled out in the NHS and beyond by her spin-out Cyted Ltd.

Professor David Hodell FRS

Hodell is the Woodwardian Professor of Geology and Director of the Godwin Laboratory for Palaeoclimate Research in the Department of Earth Sciences, and a Fellow of Clare College.

A marine geologist and paleoclimatologist, his research focuses on high-resolution paleoclimate records from marine and lake sediments, as well as mineral deposits, to better understand past climate dynamics. Hodell is a fellow of the American Geophysical Union and the American Association for the Advancement of Science. He has received the Milutin Milankovic Medal.

Professor Eric Lauga FRS

Lauga is Professor of Applied Mathematics in the Department of Applied Mathematics and Theoretical Physics, where his research is in fluid mechanics, biophysics and soft matter. Lauga is the author, or co-author, of over 180 publications and currently serves as Associate Editor for the journal Physical Review Fluids.

He is a recipient of three awards from the American Physical Society: the Andreas Acrivos Dissertation Award in Fluid Dynamics, the François Frenkiel Award for Fluid Mechanics and the Early Career Award for Soft Matter Research. He is a Fellow of the American Physical Society and of Trinity College.

Professor George Malliaras FRS

Malliaras is the Prince Philip Professor of Technology in the Department of Engineering, where he leads a group that works on the development and

translation of implantable and wearable devices that interface with electrically active tissues, with applications in neurological disorders and brain cancer.

Research conducted by Malliaras has received awards from the European Academy of Sciences, the New York Academy of Sciences, and the US National Science Foundation, among others. He is a Fellow of the Materials Research Society and of the Royal Society of Chemistry.

Professor Lloyd Peck FRI FRSB FRS

Peck is a marine biologist at the British Antarctic Survey and a fellow at Wolfson College, Cambridge.

He identified oxygen as a factor in polar gigantism and identified problems with protein synthesis as the cause of slow development and growth in polar marine species. He was awarded a Polar Medal in 2009, the PLYMSEF Silver medal in 2015 and an Erskine Fellowship at the University of Canterbury, Christchurch in 2016-2017.

Professor Oscar Randal-Williams FRS

Randal-Williams is the Sadleirian Professor of Pure Mathematics in the Department of Pure Mathematics and Mathematical Statistics.

He has received the Whitehead Prize from the London Mathematical Society, a Philip Leverhulme Prize, the Oberwolfach Prize, the Dannie Heineman Prize of the Göttingen Academy of Sciences and Humanities, and was jointly awarded the Clay Research Award.

Randal-Williams is one of two managing editors of the Proceedings of the London Mathematical Society and an editor of the Journal of Topology.

Professor Mihaela van der Schaar FRS

Van der Schaar is the John Humphrey Plummer Professor of Machine Learning, Artificial Intelligence and Medicine in the Departments of Applied Mathematics and Theoretical Physics, Engineering and Medicine.

She is the founder and director of the Cambridge Centre for AI in Medicine, and a Fellow at The Alan Turing Institute. Her work has received numerous awards, including the Oon Prize on Preventative Medicine, a National Science Foundation CAREER Award, and the IEEE Darlington Award.

Van der Schaar is credited as inventor on 35 US patents, and has made over 45 contributions to international standards for which she received three ISO Awards. In 2019, a Nesta report declared her the most-cited female AI researcher in the UK.

Cambridge research receives £5 million boost for 'world-leading' cardiovascular research

The University of Cambridge has received £5 million funding from the British Heart Foundation (BHF) to support its world-class cardiovascular disease research over the next five years, the charity has announced.

The funding will support the university to cultivate a world-class research environment that encourages collaboration, inclusion and innovation and where visionary scientists can drive lifesaving breakthroughs.

Professor Martin Bennett, BHF Professor of Cardiovascular Sciences at the University of Cambridge, said: "This is a fantastic achievement from the whole Cambridge team. This award will support our multiple research programmes

identifying new targets and treatments for vascular disease and heart failure, new ways to reduce the consequences of diabetes and obesity, and how we can get our research used to treat patients."

The Cambridge award is part of a £35 million boost to UK cardiovascular disease research from the British Heart Foundation. It comes from the charity's highly competitive Research Excellence Awards funding scheme. The £5 million award to the University of Cambridge will support researchers to:

- Combine their expertise to work on cardiovascular diseases and in populations with high unmet needs.
- Identify new markers and disease targets for a wide range of cardiovascular diseases, and test new drugs in clinical trials.
- Develop new ways to diagnose cardiovascular disease and harness the power of artificial intelligence from imaging and health records to identify people at highest risk.
- Generate user-friendly risk communication and management tools to improve the prevention and management of cardiovascular disease.

Professor Bryan Williams, Chief Scientific and Medical Officer at the British Heart Foundation, said: "We're delighted to continue to support research at the University of Cambridge addressing the biggest challenges in cardiovascular disease. This funding recognises the incredible research happening at Cambridge and will help to further its reputation as a global leader in the field.

"With generous donations from our supporters, this funding will attract the brightest talent, power cutting-edge science, and unlock lifesaving discoveries that can turn the tide on the devastation caused by heart and circulatory diseases."

Research Excellence Awards offer greater flexibility than traditional research funding, allowing scientists to quickly launch ambitious projects that can act as a springboard for larger, transformative funding applications.

The funding also aims to break down the silos that have traditionally existed in research, encouraging collaboration between experts from diverse fields. From clinicians to data scientists, biologists to engineers, the funding will support universities to attract the brightest minds, nurture new talent and foster collaboration to answer the biggest questions in heart and circulatory disease research.

The University of Cambridge has previously been awarded £9 million funding through the BHF's Research Excellence Awards scheme. This funding has supported research that will lay the foundations for future breakthroughs, including:

- Research showing that low doses of a cancer drug could improve recovery after a heart attack. The drug boosts activity of anti-inflammatory immune cells that can cause harmful inflammation in blood vessels supplying the heart. It's currently being tested in clinical trials to see if it benefits patients.
- A new risk calculator to enable doctors across the UK and Europe predict who is at risk of having a heart attack or stroke in the next 10 years with greater accuracy. The calculator has been adopted by the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice.
- Developing imaging and artificial intelligence tools to improve diagnosis of heart and vascular disease by enhancing analysis of scans for disease activity and high-risk fatty plaques. These tools can be rapidly implemented to support diagnosis, treatment and prevention.
- A study investigating whether an epilepsy medication could help to prevent strokes in people with a common gene variant. The change in the gene HDAC9 can cause it to become 'overactive' and increase

stroke risk. The epilepsy medication sodium valproate blocks the HDAC9 activity, so could reduce stroke risk in people with the variant.

- Discovery of rare and common changes in the genetic code that influences proteins and small molecules in the blood, helping us understand the development of cardiovascular diseases and identify novel drug targets.

US Food and Drug Administration approves Cambridge-developed artificial pancreas

An artificial pancreas developed by researchers at the University of Cambridge has been granted approval by the USA's Food and Drug Administration (FDA) for use by individuals with type 1 diabetes aged two and older, including during pregnancy.

This means that even more people living with the disease will be able to use this life-changing app. For the first time, the FDA authorised the use of the artificial pancreas system in pregnancy.

CamAPS FX, produced by Cambridge spinout company CamDiab (www.camdiab.com), is an Android app that can be used to help manage glucose levels in people with type 1 diabetes, including during pregnancy.

The app allows a compatible insulin pump and a compatible continuous glucose monitor to 'talk to each other', creating an artificial pancreas.

The CamAPS FX closed loop algorithm was given FDA authorisation on Thursday 23 May. It had already been CE-marked for use in the UK and the EU.

CamAPS FX creator Roman Hovorka is Professor of Metabolic Technology at the Institute of Metabolic Science and Department of Paediatrics at the University of Cambridge, where the technology was developed.

He said: "We set out to help people with type 1 diabetes and their families live better lives and we're delighted that the FDA has reviewed the safety and effectiveness of CamAPS FX and has given the technology its approval."

"It has been extensively tested and we're proud that it is considered by many to be the best algorithm out there."

CamAPS FX is already used by more than 27,000 people in 15 countries across Europe and Australia. Artificial pancreas systems such as CamAPS FX have been granted approval for wide use by the NHS in November 2023 by the National Institute for Health and Care Excellence (NICE).

Read more about the CamAPS FX app

Spotlight on dementia

September is World Alzheimer's Month, which aims to raise awareness and challenge stigma surrounding Alzheimer's and dementia. Look out for the latest campaign from our Join Dementia Research service supporting this event.

Across the UK, there has been a focus on research into dementia for a number of years. There was wide media coverage in the spring about blood tests that can diagnose dementia being a step closer. Researchers will carry out countrywide trials to identify accurate and quick blood tests that can revolutionise dementia diagnosis. The NIHR is contributing almost £1m to the

new research effort.

Researchers based at leading Scottish universities are helping to develop future treatments for dementia thanks to support from Alzheimer's Research UK. This includes understanding more about the link between sleep and Alzheimer's disease, and investigating how the protective blood brain barrier becomes damaged by the diseases that cause dementia.

A new brain stimulation study is looking for people with Alzheimer's disease to take part. The study uses small amounts of electricity to stimulate the brain in people with mild cognitive impairment or Alzheimer's disease. The aim is to see if this can help keep the part of the brain which is responsible for memory active, whilst delaying symptoms of Alzheimer's disease.

Another study is exploring views on new technology designed to locate missing people with dementia. Family members are being asked for their views on using face-matching technology and an online form to locate missing family members with dementia faster.

Register today for our Join Dementia Research service to access these studies. Or if you want to read about some of the latest dementia research, take a look at NIHR Evidence.

Global spotlight on Cambridge heart trial

Results of an NIHR Cambridge BRC and NIHR Cambridge CRF supported trial, which may help prevent patients from having repeat heart attacks, will be presented at the 30th European Society of Cardiology (ESC) Congress, the largest cardiology conference globally.

The IVORY and IVORY FINALE trial looked at whether a low dose of the cancer drug, known as aldesleukin, could increase the activation of immune cells shown to protect the heart and help patients who have had a heart attack.

Current treatment for heart attacks centres on the re-establishment and maintenance of blood flow in the coronary arteries using blood thinners, with or without stents, as well as cholesterol lowering medication. Despite current optimal therapy, heart attacks can re-occur.

The team believes the immune system is an important process in the development of atherosclerosis (plaque disease in arteries) which has not been directly harnessed in these patients and attempted to target it using a novel approach.

The researchers found in a previous trial that low doses of aldesleukin, a drug normally used to treat kidney cancer (at much higher doses), stimulates the production of protective immune cells, called Tregs, safely in patients with heart attacks.

In the current trial, they tested to see if the drug reduced inflammation in the arteries of patients after an initial heart attack, as inflammation in the arteries has previously been associated with an increase in the risk of recurrent heart attacks and death.

The study was led by researchers at Cambridge University Hospitals (CUH) and the University of Cambridge (UofC) as well as Royal Papworth Hospital, and was supported by the Medical Research Council, the British Heart Foundation, the NIHR Cambridge Biomedical Research Centre and the NIHR Cambridge Clinical Research Facility.

The results will be unveiled at the ‘late-breaking’ sessions of the 30th European Society of Cardiology (ESC) Congress 2024 in London on 30 August and will be presented by Dr Rouchelle Sriranjan, an interventional cardiology registrar and NIHR clinical lecturer in cardiology, pictured right.

CUH consultant clinical pharmacologist, affiliated associate professor and trial chief investigator, Dr Joseph Cheriyan, said: “We are delighted to be presenting these novel data at the ESC and particularly in the late breaking session, which is a highlight of the conference.

“This study was the product of very intense work by many different teams on the campus in very sick patients and demonstrates the importance of collaborative teamwork. We are very grateful to the patients for their time and dedication to our trial.”

Dr Stephen Hoole was the trial lead for Royal Papworth Hospital, whilst Professor Rudd led the imaging component for the trial.

Professor Ziad Mallat, BHF professor of cardiovascular medicine, UofC, who conceived the trial said: “If positive, this is potentially a new treatment approach that boosts our immune defence mechanisms to tame heart attacks. It could also be an important step forward in the treatment of patients with heart attacks which needs continued exploration.

“Our results should be of interest to the wider cardiovascular community. In addition to our supporters and funders, we would like to thank everyone who has worked so hard on the trial, especially the patients who have taken part.”

Use MyChart?

Did you know you can set your research preferences?

Patients at Cambridge University Hospitals can now use the patient portal MyChart to set their preferences about hearing about research opportunities. Patients who give their consent for contact can be contacted by research teams at CUH about research opportunities that may be relevant for them.

MyChart is free to **sign up** for and available to all CUH patients. You can change your preferences about research contact at any time in MyChart.

You have received this email because you previously expressed an interest in receiving updates from the PPI Team at NIHR Cambridge BRC. If you no longer wish to receive emails from us, please email cuh.ppi@nhs.net to unsubscribe.